|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-4-28
|
|
pubmed:abstractText |
Cyclooxygenase (COX)-2 selective inhibitors have been shown to have comparable efficacy to nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Large outcome studies have shown that patients with OA and RA not taking low-dose aspirin have fewer symptomatic and complicated upper GI events when treated with COX-2 selective inhibitors than with nonselective NSAIDs. When used in recommended dosages, there is no convincing evidence that patients treated with COX-2 selective inhibitors have an increased incidence of cardiovascular thrombotic events, including non-fatal myocardial infarction, than patients treated with either placebo or nonselective NSAIDs other than naproxen. Co-therapy with low-dose aspirin is recommended in patients with OA and RA at increased risk for cardiovascular events; the need for gastroprotective therapy in such patients is controversial.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-10750251,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-10874543,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-10979111,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-11087881,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-11173046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-11496855,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-11695246,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-11695247,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-11696466,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-11752357,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-11792343,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-11796408,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-12020175,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-12039807,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-12086290,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-12086292,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-12086296,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-12136912,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-12180720,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-12209478,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-12242171,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-12383990,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-1834002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-8900554,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-9140046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12716445-9820370
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1478-6362
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
28-31
|
|
pubmed:dateRevised |
2010-7-21
|
|
pubmed:meshHeading |
pubmed-meshheading:12716445-Arthritis,
pubmed-meshheading:12716445-Aspirin,
pubmed-meshheading:12716445-Cyclooxygenase 2,
pubmed-meshheading:12716445-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:12716445-Cyclooxygenase Inhibitors,
pubmed-meshheading:12716445-Digestive System,
pubmed-meshheading:12716445-Drug Therapy, Combination,
pubmed-meshheading:12716445-Humans,
pubmed-meshheading:12716445-Isoenzymes,
pubmed-meshheading:12716445-Membrane Proteins,
pubmed-meshheading:12716445-Prostaglandin-Endoperoxide Synthases
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients.
|
|
pubmed:affiliation |
Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA. mhochber@umaryland.edu
|
|
pubmed:publicationType |
Editorial
|
